SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker
•Download as PPT, PDF•
0 likes•826 views
Presentation by Sijme Zeilemaker of ToBBB for the Science meets Business café of 12 sep 2013. This event was held in the BioPartner Accelerator building in Leiden.
SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker
- 1. Safely Enhancing Drug Delivery to the CNS An Innovative Platform Technology Sijme Zeilemaker, MSc Business Development Associate to-BBB Science meets Business September 2013
- 2. Background 2005 – 2011 Biomedical Sciences at Leiden University 2008: LACDR internship Master Biomedical Sciences – Management Science Based Business 2010: Business Internship
- 3. A start-up company in neuroscience… Blood-Brain Barrier 600 kilometer Every neuron has its own capillary
- 4. • G-Technology® : safe brain delivery technology • Glutathione: safe brain targeting mechanism • PEG-liposomes: well-established delivery technology • Strong patent protection on any drug combination to-BBB’s brain drug delivery platform
- 5. G-Technology: mechanistic validation in vitro
- 6. 5 times more in brain improved anti-cancer effect b r a in c a n c e r ( U 8 7 M G - l u c ) t r e a t e d w i t h D O X I L o r 2 B 3 - 1 0 1 0 4 8 1 2 1 6 2 0 2 4 2 8 0 % 2 5 0 0 % 5 0 0 0 % 7 5 0 0 % 1 0 0 0 0 % 1 2 5 0 0 % s a lin e D O X I L 5 m g / k g 2 B 3 - 1 0 1 5 m g / k g d a y s a f t e r s t a r t o f t r e a t m e n t G-Technology: mechanistic validation in vivo Doxil/Caelyx: PEG liposomal doxorubicin 2B3-101: Glutathione-PEG liposomal doxorubicin
- 7. 2B3-101: confirming the safe brain delivery platform Lead product 2B3-101 treating patients with brain cancer •Therapeutic dosages reached with a predictable safety profile •Favorable long circulation plasma half-life of 64 hours •Early signs of clinical efficacy with partial responses and stable disease •Results to be presented at European Cancer Congress, Amsterdam
- 8. 2-fold business model: internal development
- 9. Enhanced uptake across CNS •Safe, endogenous mechanism Increased half life •Reduce dosing frequency Liposomal shielding •Reduce side effects Strong IP protection •Life Cycle Management 2-fold business model: pharma/biotech partnering this could be your compound!
- 10. Business Development: all about partnering Pharma* : Mid-size pharma / biotech* : Grants: *examples
- 11. Business Development: getting done more… with less Pharma* : Mid-size pharma / biotech* : Grants: *examples build a leading company in brain drug development build a leading company in brain drug development